Search

Displaying results 1801 - 1810 of 10000 in total
  1. Drug

    Disopyramide

    go.drugbank.com/drugs/DB00280
    ApprovedInvestigational

    It also possesses some anticholinergic and local anesthetic properties. … A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar

    Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class Ia
  2. Drug

    Amiloxate

    go.drugbank.com/drugs/DB11207
    Approved

    Amiloxate is an EMA-approved chemical UV-filter found in over-the-counter sunscreen products at concentrations up to 10%m [F35]. … It is often referred to as isoamyl 4-methoxycinnamate or isoamyl p-methoxycinnamate. Amiloxate is a cinnamic acid derivative with an anti-inflammatory activity [A32916].

    Mixtures: The History of Whoo Jin Hae Yoon Sun
  3. Drug

    Nuvaxovid

    go.drugbank.com/drugs/DB15810
    ApprovedInvestigational

    [L42450,L42965] An updated formulation covering the Omicron XBB.1.5 subvariant was approved in October 2023 in the EU[L48897] and in December 2023 in Canada. … a productive infection in humans.

  4. Drug

    Tezepelumab

    go.drugbank.com/drugs/DB15090
    ApprovedInvestigational

    [A243764, A243769, A243774] Tezepelumab is a human monoclonal IgG2λ antibody directed against TSLP produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. … It was granted FDA approval on December 17, 2021, and is currently marketed under the trademark TEZSPIRE by Amgen/AstraZeneca.

  5. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    [L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … [L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age.

  6. Drug

    Ceftobiprole

    go.drugbank.com/drugs/DB04918
    ApprovedWithdrawn

    [L50467] It received its first approval in Canada in October 2017 for use in certain patients with bacterial pneumonia,[L50472] and was subsequently approved in the United States with additional indications … for skin and skin structure infections and bacteremia in April 2024.

  7. Drug

    Glycyrrhizic acid

    go.drugbank.com/drugs/DB13751
    ApprovedInvestigational

    [T204] Glycyrrhizic acid has been developed in Japan and China as a hepatoprotective drug in cases of chronic hepatitis. … When extracted from the plant, it can be obtained in the form of ammonium glycyrrhizin and mono-ammonium glycyrrhizin.

  8. Drug

    Doxepin

    go.drugbank.com/drugs/DB01142
    ApprovedInvestigational

    [L5977] Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant.[L5971] However, in 2010 it was approved for the treatment of insomnia. … [T83] In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline

  9. Drug

    Betula pendula tar oil

    go.drugbank.com/drugs/DB11361
    ApprovedNutraceutical

    Betula pendula tar oil is an essential oil found in the buds of the plant with the same name. … [T219] The utilization of this product started during the second world war in the Sovietic Union.

  10. Drug

    Camrelizumab

    go.drugbank.com/drugs/DB14776
    Investigational

    Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).